Targeted therapy plus immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hepatocellular carcinoma (liver cancer).
- Your liver cancer must not be removable by surgery (unresectable) and be at an intermediate or advanced stage.
- Your liver function must be adequate, as shown by a Child-Pugh score of A or B7.
- You must be able to perform daily activities with minimal assistance (ECOG performance status 0-2).
- You must agree to use effective contraception if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.